Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)”

7 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 7 of 7 results

Not applicableActive Not RecruitingNCT04632953
What this trial is testing

Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program

Who this might be right for
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Ultragenyx Pharmaceutical Inc 150
Not applicableStudy completedNCT03768817
What this trial is testing

Clinical Outcome of Triheptanoin Treatment in Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Treated Under Expanded Access Program

Who this might be right for
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Ultragenyx Pharmaceutical Inc 20
Large-scale testing (Phase 3)Active Not RecruitingNCT05933200
What this trial is testing

Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD

Who this might be right for
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Ultragenyx Pharmaceutical Inc 69
Not applicableEnded earlyNCT04812106
What this trial is testing

Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program

Who this might be right for
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Ultragenyx Pharmaceutical Inc 8
Not applicableAvailableNCT03773770
What this trial is testing

Expanded Access to Triheptanoin

Who this might be right for
Long Chain Fatty Acid Oxidation Disorders
Ultragenyx Pharmaceutical Inc
Testing effectiveness (Phase 2)Study completedNCT02214160
What this trial is testing

Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies

Who this might be right for
Carnitine Palmitoyltransferase (CPT I or CPT II) DeficiencyVery Long Chain Acyl-CoA Dehydrogenase (VLCAD) DeficiencyLong-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency+2 more
Ultragenyx Pharmaceutical Inc 94
Testing effectiveness (Phase 2)Study completedNCT01886378
What this trial is testing

UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)

Who this might be right for
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)Carnitine Palmitoyltransferase (CPT II) DeficiencyVery Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency+2 more
Ultragenyx Pharmaceutical Inc 29